AvalehtGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
Viimane sulgemishind
7,18 $
Tänane vahemik
7,15 $ - 7,33 $
Aasta vahemik
5,79 $ - 9,96 $
Turuväärtus
5,99 mld USD
Keskmine maht
984,18 tuh
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(EUR) | dets 2024info | Y/Y muutus |
---|---|---|
Käive | 1,98 mld | 11,66% |
Põhitegevusega seonduv kulu | 353,12 mln | 20,32% |
Puhastulu | 68,97 mln | 76,86% |
Puhaskasumimarginaal | 3,49 | 58,64% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 495,68 mln | −11,49% |
Tõhus maksumäär | 60,20% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(EUR) | dets 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 1,00 mld | 55,40% |
Kogu vara | 21,41 mld | 1,97% |
Kõik kohustused | 12,80 mld | −5,05% |
Kogu omakapital | 8,61 mld | — |
Emiteeritud aktsiate arv | 680,41 mln | — |
Hinna ja väärtuse suhe P/B | 0,83 | — |
Varade tasuvus | 5,08% | — |
Kapitali tasuvus | 5,79% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(EUR) | dets 2024info | Y/Y muutus |
---|---|---|
Puhastulu | 68,97 mln | 76,86% |
Põhitegevuse rahakäive | 514,62 mln | 208,54% |
Investeeringute raha | −178,31 mln | −28,31% |
Finantseerimise raha | −27,16 mln | −185,08% |
Raha ja raha ekvivalentide muutus | 334,84 mln | 658,87% |
Tasuta rahavoog | 162,44 mln | 123,56% |
Teave
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Tegevjuht
Asutatud
18. nov 1940
Veebisait
Töötajate arv
23 833